Supernus Pharmaceuticals (0LB2) Income Statement
0 Followers
Supernus Pharmaceuticals Income Statement
Last quarter (Q3 2026), Supernus Pharmaceuticals's total revenue was $356.00M, an increase of 13.38% from the same quarter last year. In Q3, Supernus Pharmaceuticals's net income was $137.00M. See Supernus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.24B | $ 1.19B | $ 1.09B | $ 901.00M | $ 791.00M | |
| $ 993.00M | $ 957.00M | $ 919.00M | $ 750.00M | $ 664.00M | |
| $ 728.00M | $ 925.00M | $ 1.07B | $ 831.00M | $ 451.00M | |
| Depreciation and Amortization | $ 20.00M | $ 28.00M | $ 15.00M | $ 16.00M | $ 22.00M |
| $ 304.00M | $ 83.00M | $ -99.00M | $ -46.00M | $ 238.00M | |
| $ 265.00M | $ 32.00M | $ -156.00M | $ -81.00M | $ 213.00M | |
| $ -26.00M | $ -18.00M | $ 7.00M | $ -8.00M | $ -23.00M | |
| $ 239.00M | $ 14.00M | $ -149.00M | $ -89.00M | $ 190.00M | |
| $ 210.00M | $ 2.00M | $ -129.00M | $ -44.00M | $ 205.00M | |
| Per Share Metrics | |||||
| Basic EPS | $ 1.68 | $ 0.02 | $ -0.94 | $ -0.37 | $ 1.38 |
| Diluted EPS | $ 1.64 | $ 0.01 | $ -0.91 | $ -0.37 | $ 1.31 |
| Weighted Average Shares Outstanding | 125.00M | 132.00M | 137.31M | 139.01M | 145.66M |
| Weighted Average Shares Outstanding (Diluted) | 128.00M | 133.00M | 141.80M | 139.01M | 154.23M |
Currency in USD
